Khorana score (VTE risk during chemotherapy)
For cancer outpatients before starting chemotherapy. Cancer site 0–2, other items 1 point each. Symptomatic VTE over a median of 2.5 months (derivation/validation): 0 points 0.8%/0.3%, 1–2 points 1.8%/2%, ≥ 3 points 7.1%/6.7%. Khorana AA et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902–7. PMID 18216292.
More about this tool
Enter the values and the result appears immediately. Formula and interpretation follow the original publication cited below. Free, no account – your entries stay in your browser.
For orientation only. Does not replace clinical judgement; verify results before clinical decisions.
More calculators: Thrombosis and pulmonary embolism
- Wells score for deep vein thrombosis (DVT)
- Wells score for pulmonary embolism (PE)
- Revised Geneva score (pulmonary embolism)
- PERC rule (pulmonary embolism rule-out)
- sPESI (simplified Pulmonary Embolism Severity Index)
- Padua Prediction Score (VTE risk in medical inpatients)
pubmed.info sets no tracking cookies and builds no user profiles. Visits are counted anonymously (cookieless, shortened IP addresses). Ads from Google appear only according to your consent choice.